Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Houot R, Cartron G, Bijou F, de Guibert S, Salles GA, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas RO, Moluçon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, Van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F.
Houot R, et al. Among authors: bijou f.
Leukemia. 2019 Mar;33(3):776-780. doi: 10.1038/s41375-018-0282-y. Epub 2018 Oct 5.
Leukemia. 2019.
PMID: 30291335
Free article.
Clinical Trial.
No abstract available.